Filgrastim (r-metHuG-CSF) in the 21st century: SD/01

被引：34

作者：

Morstyn, G

Foote, MA

Walker, T

Molineux, G

机构：

[1] Amgen Inc, Thousand Oaks, CA 91230 USA

[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

来源：

ACTA HAEMATOLOGICA | 2001年 / 105卷 / 03期

关键词：

filgrastim; chemotherapy; neutropenia; pegylated molecule; preclinical studies; clinical studies; myelosuppression; lung cancer; normal volunteer;

D O I：

10.1159/000046557

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SD/01, a sustained-duration molecule, has been developed by adding a poly [ethylene glycol] molecule to the filgrastim molecule. The pegylation does not change the properties of filgrastim, except that the plasma clearance is decreased and plasma half-life is increased. Increasing the duration of the biological effects of filgrastim may offer certain groups of patients better benefits. Early clinical studies have been encouraging with no serious toxicities noted. Copyright (C) 2001 S. Karger AG, Basel.

引用

页码：151 / 155

页数：5

共 10 条

[1]

Blackwell S., 1994, FILGRASTIM R METHUG, P103

[2] QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].

BODEY, GP ;

BUCKLEY, M ;

SATHE, YS ;

FREIREICH, EJ .

ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+

[3] REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].

CRAWFORD, J ;

OZER, H ;

STOLLER, R ;

JOHNSON, D ;

LYMAN, G ;

TABBARA, I ;

KRIS, M ;

GROUS, J ;

PICOZZI, V ;

RAUSCH, G ;

SMITH, R ;

GRADISHAR, W ;

YAHANDA, A ;

VINCENT, M ;

STEWART, M ;

GLASPY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170

[4]

DELGADO C, 1992, CRIT REV THER DRUG, V9, P249

[5] Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy [J].

Johnston, E ;

Crawford, J ;

Blackwell, S ;

Bjurstrom, T ;

Lockbaum, P ;

Roskos, L ;

Yang, BB ;

Gardner, S ;

Miller-Messana, MA ;

Shoemaker, D ;

Garst, J ;

Schwab, G .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2522-2528

[6]

LAYTON JE, 1989, BLOOD, V74, P1303

[7] A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans [J].

Molineux, G ;

Kinstler, O ;

Briddell, B ;

Hartley, C ;

McElroy, P ;

Kerzic, P ;

Sutherland, W ;

Stoney, G ;

Kern, B ;

Fletcher, FA ;

Cohen, A ;

Korach, E ;

Ulich, T ;

McNiece, I ;

Lockbaum, P ;

Miller-Messana, MA ;

Gardner, S ;

Hunt, T ;

Schwab, G .

EXPERIMENTAL HEMATOLOGY, 1999, 27 (12) :1724-1734

[8]

OSSLUND T, 1998, FILGRASTIM RMETHUGCS, P41

[9]

Roskos L, 1998, FILGRASTIM R METHUG, P51

[10] RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR REDUCES THE INFECTIOUS COMPLICATIONS OF CYTOTOXIC CHEMOTHERAPY [J].

TRILLETLENOIR, V ;

GREEN, J ;

MANEGOLD, C ;

VONPAWEL, J ;

GATZEMEIER, U ;

LEBEAU, B ;

DEPIERRE, A ;

JOHNSON, P ;

DECOSTER, G ;

TOMITA, D ;

EWEN, C .

EUROPEAN JOURNAL OF CANCER, 1993, 29A (03) :319-324

← 1 →